STRONGMHealthcare·Biotechnology#235 in industry

Sutro Biopharma, Inc.

+102.1% · 90d

$33.59

+0.26 (+0.78%)

After-Hours $33.25(-0.34)

News

(2)

April 2026

Apr 22, 20265 days agoARSHealthcare

Sutro Files Amendment (ARS) Without Reporting Specific Operational Updates

STROSUTRO BIOPHARMA, INC.

⚠️ **CRITICAL NOTICE:** The provided document content is empty. The input contains only the metadata wrapper for an SEC filing (an ARS from 2007-11-10), but the actual text, PDF, and substantive data are missing. As an expert financial analyst, I cannot summarize or interpret content that has not b

Read summaryView on SEC EDGAR

Apr 22, 20265 days agoDEF 14AHealthcare

Sutro Biopharma STRO Shareholders to Vote on Directors, Auditor, Pay

STROSUTRO BIOPHARMA, INC.

# 🧾 What This Document Is This is a **DEF 14A, or "Definitive Proxy Statement."** Think of it as the official invitation and agenda for Sutro Biopharma's annual shareholder meeting. It's not a report on quarterly earnings; instead, it's where the company asks its owners (the shareholders) to vote o

Read summaryView on SEC EDGAR

Key Data

Market Cap$556.5M

Open$33.17

Prev Close$33.33

Day Range$32.55 – $34.26

52W Range$6.70 – $36.00

Volume190,700

P/E (TTM)—

EPS$-22.49

Dividend Yield—

Beta1.31

Profit Margin-186.45%

Revenue Growth-21.40%

Price Target$32.11(-4.4%)

Analyst Ratings

Strong Buy11 analysts

Buy 9Hold 1Sell 1

About

Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, cervical cancer, colorectal cancer, pancreatic ductal adenocarcinoma, endometrial cancer, and bladder cancer. The company also develops VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease in adults and adults and infants; and STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors, such as triple negative breast cancer, non-small cell lung cancer, and ovarian cancer, as well as hematological cancers. Sutro Biopharma, Inc. has collaboration and license agreements with Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; Ipsen to develop and commercialize STRO-003, an ADC targeting ROR1; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Healthcare · Biotechnology

137 employees

www.sutrobio.com